RxDoctor Payments Data

Susan Shields, PA

Physician Assistant · Las Vegas, NVNPI 1538244512

Payments from drug & device makers

$1,018in general payments, 2019–2025

Across 16 payments — averaging $63.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$178
  • Boehringer Ingelheim$173
  • Pfizer$130
  • Ultragenyx Pharmaceutical Inc.$122
  • Recordati_rare_diseases_inc.$121
  • Eisai Inc.$120
  • plus $175 from 4 others

What the payments were for

  • Food & beverage$1,018100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,018 in reported general payments places this provider in the 60th percentile of 881 physician assistant providers in Nevada.

See all physician assistant providers in Nevada

Medicare billing

Part B allowed, 2024
$32,050
Medicare patients
85
Services billed
430

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide96$147,757
EliquisApixaban83$119,313
TrulicityDulaglutide31$54,660
FarxigaDapagliflozin Propanediol29$47,558
XifaxanRifaximin15$47,080
XareltoRivaroxaban22$36,747
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$29,783
JardianceEmpagliflozin28$28,020
MounjaroTirzepatide23$25,945
Spiriva RespimatTiotropium Bromide17$25,893
EntrestoSacubitril/Valsartan11$21,501
TradjentaLinagliptin12$17,769
MyrbetriqMirabegron11$14,584
SymbicortBudesonide/Formoterol Fumarate11$6,086
Lantus SolostarInsulin Glargine,hum.Rec.Anlog19$5,035

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$130$119,31383 claims
Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta$173$71,68357 claims
AstraZenecaFarxiga, Symbicort$178$53,64440 claims
GSKTrelegy Ellipta$109$29,78317 claims
NovartisEntresto$18$21,50111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 881 physician assistant providers in Nevada.

Other physician assistant in Las Vegas

See the full list for Nevada

Where these figures come from

Is this you, or does something look wrong? →